Hemoglobin A₂ Lowered by Iron Deficiency and α-Thalassemia: Should Screening Recommendation for β-Thalassemia Change?

Srdjan Denic, Mukesh M. Agarwal, Bayan Al Dabbagh, Awad El Essa, Mohamed Takala, Saad Showqi, and Javed Yassin

1 Department of Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE
2 Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, Abu Dhabi, UAE
3 Al Ain Hospital, P.O. 1006, Al Ain, Abu Dhabi, UAE

Correspondence should be addressed to Srdjan Denic; s.denic@uaeu.ac.ae

Received 23 December 2012; Accepted 18 February 2013

Copyright © 2013 Srdjan Denic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Screening for β-thalassemia trait (BTT) relies on measuring hemoglobin (Hb) A₂. Since multiple factors can affect HbA₂ levels, the screening can become unreliable. In 1356 healthy Arabs enrolled into a federally funded premarital BTT screening program, the effects of iron deficiency (ID), α⁺-thalassemia trait, gender, smoking, and tribalism on HbA₂ were studied. The complete blood count and hemoglobin fractions were determined on the entire cohort; serum ferritin (<15 μg/L) in 391 subjects was used to determine ID. BTT was present in 29 (2.1%) subjects (HbA₂ > 3.5%). Among 77 (20.3%) subjects with ID, the mean HbA₂ (2.30 ± 0.23%) was 0.2% lower than in subjects without iron deficiency (2.50 ± 0.24%, 𝑃< 0.0001). In 65 (38%)/172 subjects with phenotypic α⁺-thalassemia trait, the mean HbA₂ (2.43 ± 0.24%) was 0.13% lower than in subjects without α⁺-thalassemia trait, 𝑃< 0.0001. The mean HbA₂ did not differ between males and females, smokers and nonsmokers, and between the tribes. Thus, 35 (2.6%) subjects with HbA₂ between 3.2 and 3.5% were at a risk of false negative diagnosis of BTT. Since iron deficiency and α⁺-thalassemia are both common and both lower HbA₂, modifications in screening recommendations for BTT are proposed.

1. Introduction

Screening for β-thalassemia trait (BTT) depends on measuring hemoglobin (Hb) A₂ accurately. However, since many factors like iron deficiency, α-thalassemia, β-gene mutations, gender, and smoking may affect HbA₂ levels, the screening of BTT can be compromised [1–5]. The United Arab Emirates (UAE) is a multiethnic country with a BTT screening program because of a heavy burden of β-thalassemia disease. Consanguinity is common and marriages in the native population are arranged within the same tribe, which restricts gene flow and produces a heterogeneous distribution of BTT [6, 7]. As a preventive measure, mandatory federal premarital screening has been instituted throughout the UAE. In this population, though iron deficiency is common, iron stores are not routinely evaluated during the screening for BTT. In addition, α-thalassemia mutations are also frequent; this is important for BTT screening since their coinheritance with β-thalassemia mutations may lower the level of HbA₂. Furthermore, α-thalassemia alters MCV and MCH, which adds to the risk of a missed diagnosis of BTT [2, 8]. In the UAE, 44 different β-thalassemia mutations have been reported though their phenotype, and the prevalence of silent mutations have not been systematically investigated [9–13]. Moreover, in this population the differences in lifestyle between genders might affect HbA₂; for example, smoking is commoner among men, and the effect of smoking on HbA₂ has not been studied. Women in this society are more prone to chronic nutritional disorders (e.g., obesity and type 2 diabetes), which may cause a high prevalence of iron
definitions for iron deficiency were used: (1) ferritin < 15 μg/L (which is more specific) and (2) ferritin < 30 μg/L (which is more sensitive) [17]. α-thalassemia trait was phenotypically defined when a subject had (1) MCV < 80 fL, (2) HbA2 ≥ 3.5%, (3) ferritin ≥ 30 μg/L, and (4) RDW ≤ 14.0. Subjects with MCV > 80 fL, HbA2 ≤ 3.5%, ferritin ≥ 30 μg/L, and RDW ≤ 14.0 were considered to have a normal genotype. In this population, α-thalassemia trait is due to α⁺-deletions and mutations [8, 18]. Kinship groups (tribes) were defined by family names of study subjects and were coded to preserve confidentiality. A trained nurse took the basic clinical history documenting the smoking status, gender, and a family history of thalassemia.

2.4. Statistics. Standard descriptive statistical methods were used. In analysis, cutoff value of >3.5% was used to separate normal from elevated HbA₂ levels. Student-\(t\) test was used to compare means of Hba₂ in both groups with other variables and between subgroups. Chi-squared test was used for no parametric variables. ANOVA test was used to test the equality of Hba₂ means between major tribes. Statistical significance was defined with two-tailed \(P \leq 0.05\). Data were coded and analyzed with SPSS statistical software version 19.0 (Chicago, IL, USA).

3. Results

3.1. Sex, Age, and Subjects with and without BTT. Of 1356 subjects, 50.6% were female. The mean age of males (26.0 ± 6.7 years, range 16–69) was three years higher than that of the females (22.9 ± 4.6 years, range 11–44). Among these 1356 consecutive cases, 29 (2.1%) had BTT. The distribution of Hba₂ is shown in Figure 1.

3.2. Hemoglobin A₂ in Non-BTT. In 1,327 subjects without BTT, the mean Hba₂ level was 2.61 ± 0.31%.

3.2.1. Hemoglobin A₂ in Iron Deficiency. In all 77/379 (20.3%) iron deficient subjects, defined as ferritin <15 μg/L, the mean Hba₂ (2.30 ± 0.23%) was 0.2% lower than in subjects without iron deficiency (2.50 ± 0.24%, \(P < 0.0001\)). When iron deficiency was defined as ferritin <30 μg/L, iron deficient individuals (138/379) had a mean Hba₂ (2.39 ± 0.25%) that was 0.11% lower than in individuals without iron deficiency (2.50 ± 0.24%, \(P < 0.0001\)). In 75/198 (38%) iron deficient females (ferritin < 15 μg/L), the mean Hba₂ (2.31 ± 0.23%) was 0.17% lower than in iron sufficient females (2.48 ± 0.25%, \(P < 0.0001\)). When iron deficiency in females was defined as ferritin <30 μg/L, the mean Hba₂ (2.38 ± 0.25%) was 0.1% lower than in noniron deficient females (2.48 ± 0.26%, \(P = 0.01\)). Only 2 of 190 males had ferritin <15 μg/L.

3.2.2. Hemoglobin A₂ in α⁺-thalassemia Trait. The phenotypically derived diagnosis of α-thalassemia trait is more reliable in males because they are rarely iron deficient. In 65 males with phenotypic α⁺-thalassemia trait, the mean Hba₂ (2.44 ± 0.20%) was 0.13% lower than in 107 without
3.3.1. Hemoglobin A
to 6.2%. 

3.3. Hemoglobin A
have nonthalassemic values of HbA
values between 3.6% and 3.9% are iron deficient, they could
value are 0.4%. Thus, if individuals with BTT and HbA
comprising 62% of subjects (data not shown).

level in subjects without BTT did not differ between 14 tribes

3.2.4. Hemoglobin A
in Smokers. Males smoked tobacco considerably more often (39%, 68/174) than females (2%, 4/171). The red cell count, mean Hb, and mean HbA
levels were not different between male smokers and nonsmokers
(P = 0.42–0.76).

3.2.5. Hemoglobin A
in Kinship Groups. The mean HbA
level in subjects without BTT did not differ between 14 tribes comprising 62% of subjects (data not shown).

3.2.6. Hemoglobin A
in Borderline Range. In iron deficient subjects (ferritin < 15 µg/L), two standard deviations of HbA
value are 0.4%. Thus, if individuals with BTT and HbA
values between 3.6% and 3.9% are iron deficient, they could have nonthalassemic values of HbA
that are between 3.2% and 3.5%. They are at a risk of false negative diagnosis of BTT (Figure 2). We found that 35 of 1356 subjects (2.6%) have HbA
in the range of 3.2% and 3.5%, a group in which information about iron status is vital and most critical.

3.3. Hemoglobin A
in BTT. In 29 subjects with BTT, the mean HbA
was 5.2 ± 0.5%, with values ranging from 3.9% to 6.2%.

3.3.1. Hemoglobin A
in BTT and Iron Deficiency. Among 12
informative cases of BTT, five with iron deficiency (ferritin
< 15 µg/L) had lower mean HbA
(5.24 ± 0.23%) than seven without iron deficiency
(5.41 ± 0.45%, P = 0.45).

4. Discussion

This study substantiates that HbA
is lower if iron deficiency or the α-thalassemia trait are present; it is unaffected by gender, smoking, or tribal allegiance. However, many important questions remain: How valid are these findings? Can they be extrapolated to subjects with BTT? How should these observations impact screening for BTT?

HbA
was lower in iron deficient BTT carriers compared to noniron deficient BTT carriers; however, the difference was not statistically significant. This finding can be attributed to the small sample size or heterogeneity of β-thalassemia mutations. In subjects without BTT, HbA
was lower in individuals who were more iron depleted (ferritin < 15 µg/L) than subjects who were less iron depleted (ferritin < 30 µg/L). This suggests a “dose effect” of body iron stores on the level of HbA
. In this study, two standard deviation dispersions of HbA
value around the mean were 0.4% for all subjects and 0.46% for females with iron deficiency. Therefore, subjects with iron deficiency and HbA
between 3.2% and 3.5% could theoretically have BTT, that is, a false negative test. Of the screened population, 2.6% were within this range of borderline HbA
values. As it is unknown how many of them have β-thalassemia mutation (false negative cases are presumed to be rare), the value of routinely evaluating iron stores during BTT screening cannot be ignored. Studies have shown that iron deficiency lowers (while iron repletion increases) HbA
; thereby, the diagnosis from non-BTT carrier may change to BTT carrier and vice versa (reviewed in 1). Since 38% of females and <1% of males in our population had ferritin < 15 µg/L, evaluating routinely iron stores (i.e., serum ferritin) among females alone seems appropriate to facilitate effective screening. In addition, serum ferritin (which is not routinely measured during screening) is often requested if borderline HbA
is encountered. In our study population, additional reasons warrant evaluation of iron stores during premarital screening. A diagnosis (and subsequent treatment) of iron deficiency in our population would benefit a large number of females and subsequently their infants since most women become pregnant after marriage. Moreover, with the high prevalence of α
-thalassemia trait, iron deficiency in females, and BTT in our population, knowledge about iron stores will help community physicians to differentiate between these disorders, all of which are common causes of microcytosis and anemia in our population [7, 15]. Thus, the additional cost of serum ferritin (added to premarital screening of females) in our population is justified due to the high number of women and their children who would benefit from it.

The high frequency of α
-thalassemia in this population, one of the highest in the world, may also affect the diagnosis of BTT [15, 18]. We confirmed that subjects with α-thalassemia trait (phenotypically derived) have lower levels of HbA,
an observation also observed by others [2]. However, whether coinheritance of α
-thalassemia affects HbA
level in subjects with BTT is less certain. In a Chinese population with BTT, the HbA
level was unaffected by coinheritance of one α-globin gene deletion and two α-globin gene deleted in cis (α
) [1]. In our population, α-thalassemia trait is due to two α-globin gene deleted in trans (α
) [8, 18]. In patients with
BTT and coinherited $\alpha$-thalassemia resulting in hemoglobin H disease, HbA2 was found to be normal or elevated [19]. A coinheritance of $\beta$-thalassemia and $\alpha$-thalassemia may result in normal MCV and MCH, a type of silent BTT that could result in a false negative diagnosis of BTT [20]. In our study, only one of 91 subjects with BTT had normal MCV (data not shown). The prevalence of silent $\beta$-thalassemia mutations that result in normal level of HbA2 is unknown in our population, and such prevalence is presumed to be low. Our study was not designed to determine the frequency of such mutations. However, in some recent studies, the frequency of silent $\beta$-thalassemia mutations (resulting in normal HbA2 level) is reportedly as high as 17% in some populations with endemic BTT [21–23]. Moreover, high prevalence of both iron deficiency (38% in females in our study) and $\alpha$-gene deletion carriers (49% in other study) in the same population increases the likelihood of their coexistence in BTT carriers [15, 18]. The combined effect of iron deficiency and $\alpha$-thalassemia on HbA2 in BTT is unknown. Recently, it was found that tribalism, resulting in marriages within Kinship groups and heterogeneous distribution of BTT carriers in our population, dramatically increases odds of a BTT carrier marrying another BTT carrier [7]. Therefore, in premarital screening of our population, a combination of several factors increases the uncertainty of a false negative diagnosis of BTT. This justifies a DNA test for $\beta$-thalassemia mutation in all individuals with normal HbA2, who plan to marry BTT carriers.

In this study, we also noted that HbA2 levels were not statistically different between men and women without BTT after excluding iron deficient females from the analysis, finding which has been observed earlier [5]. In a study of BTT carriers, the mean value of HbA2 was also not different between males and females after the effect of iron status and type of $\beta$-thalassemia mutation were taken into account [1]. In general, there is no good physiological rational for sex-based differences of HbA2. Similarly, smoking in our study did not affect the level of HbA2, a finding which was also observed in one other study [5].

The type of $\beta$-thalassemia mutation is a predictor of HbA2 level [3, 4]. In one study, mutation type had a stronger influence on HbA2 level than iron deficiency [1]. Our study population has a high number of different $\beta^+$- and $\beta^0$-thalassemia mutations resulting in the heterogeneity of HbA2 levels (Figure 1) [10–13]. While normal HbA2 value did not differ between the tribes, our sample was small for this analysis in BTT carriers.

4.1. Limitations of the Study. In the study, we derived genotypes from phenotypes. Although we have previously shown that red cell parameters of phenotypically derived $\alpha$-thalassemia trait are correlated with the parameters of $\alpha$-thalassemia trait derived by genotyping, we could not diagnose coinheritance of $\alpha$- and $\beta$-thalassemias from phenotypes [15]. Due to restricted funding, ferritin was not measured in the entire cohort; the number of BTT carriers with iron deficiency was small. In addition, we extrapolated findings from subjects without BTT to those with BTT, which may not be always appropriate.

4.2. Conclusions. In this Arab population, the cumulative risk of all the factors that lower HbA2 (iron deficiency, $\alpha$-$\beta$-thalassemia, and many uninvestigated $\beta$-thalassemia mutations) is higher than appreciated. Since both iron deficiency and $\alpha$-$\beta$-thalassemia trait are common and both lower the level of HbA2, this decrease in HbA2 may cause some BTT carriers to be missed on screening. As iron deficiency is mostly confined to females, routinely measuring serum ferritin in women is justified. In addition, since marriage between two BTT carriers can be disastrous for the progeny, a DNA test for $\beta$-thalassemia mutation is warranted in all subjects without BTT who plan to marry BTT carriers. The benefit of this approach to BTT screening needs to be validated by larger studies.

Acknowledgments

The authors thank Professor Abdul Kader Saudit for his critical comments. This study was supported by the grants from UAE University.

References

[1] M. Verhovsek, C. C. So, T. O’shea et al., “Is HbA2 level a reliable diagnostic measurement for beta-thalassemia trait in people with iron deficiency?” American Journal of Hematology, vol. 87, pp. 114–116, 2012.
[2] C. L. Hartevedt and D. R. Higgs, “Alpha-thalassaemia,” Orphanet Journal of Rare Diseases, vol. 5, article 13, 2010.
[3] T. H. J. Huisman, “Levels of Hb A2 in heterozygotes and homozygotes for beta-thalassemia mutations: influence of mutations in the CACCC and ATAAA motifs of the beta-globin gene promoter,” Acta Haematologica, vol. 98, no. 4, pp. 187–194, 1997.
[4] S. L. Thein, “Genetic modifiers of $\beta$-thalassemia,” Haematologica, vol. 90, no. 5, pp. 649–660, 2005.
[5] I. S. Tarazi, M. M. Sirdah, H. El Jeadi, and R. M. Al Haddad, “Does cigarette smoking affect the diagnostic reliability of hemoglobin $\alpha$2$\beta$2 (HbA2)?” Journal of Clinical Laboratory Analysis, vol. 22, no. 2, pp. 119–122, 2008.
[6] L. I. Al-Gazali, R. Alwash, and Y. M. Abdulrazzaq, “United Arab Emirates: communities and community genetics,” Community Genetics, vol. 8, no. 3, pp. 186–196, 2005.
[7] S. Denic, B. Aden, N. Nagelkerke, and A. E. Awad, “Beta-thalassemia in Abu Dhabi: consanguinity and tribal stratification are major factors explaining the high prevalence of disease,” Hemoglobin. In press.
[8] S. El-Kalla and E. Baysal, “$\alpha$-thalassemia in the United Arab Emirates,” Acta Haematologica, vol. 100, no. 1, pp. 49–53, 1998.
[9] R. Quaife, L. Al-Gazali, S. Abbas et al., “The spectrum of $\beta$-thalassaemia mutations in the UAE national population,” Journal of Medical Genetics, vol. 31, no. 1, pp. 59–61, 1994.
[10] E. Baysal, “Molecular heterogeneity of beta-thalassemia in the United Arab Emirates,” Community Genetics, vol. 8, no. 1, pp. 35–39, 2005.
[11] E. Baysal, “Molecular basis of beta-thalassemia in the United Arab Emirates,” Hemoglobin, vol. 35, pp. 581–588, 2011.
[12] S. El-Kalla and A. R. Mathews, “Molecular characterization of $\beta$-thalassemia in the United Arab Emirates,” Hemoglobin, vol. 17, no. 4, pp. 355–362, 1993.
[13] S. El-Kalla and A. R. Mathews, “A significant β-thalassemia heterogeneity in the United Arab Emirates,” *Hemoglobin*, vol. 21, no. 3, pp. 237–247, 1997.

[14] S. W. Ng, S. Zaghloul, H. I. Ali, G. Harrison, and B. M. Popkin, “The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States,” *Obesity Reviews*, vol. 12, no. 1, pp. 1–13, 2011.

[15] S. Denic, A. K. Souid, N. Nagelkerke, S. Showqi, and G. Ballhaj, “Erythrocyte reference values in Emirati people with and without α⁺ thalassemia,” *BMC Blood Disorders*, vol. 11, article 1, 2011.

[16] I. Agouti, F. Merono, N. Bonello-Palot, and C. Badens, “Analytical evaluation of the capillaries 2 flex piercing for routine haemoglobinopathies diagnosis,” *International Journal of Laboratory Hematology*, 2012.

[17] World Health Organization, *Department of Nutrition for Health and Development. Iron Deficiency Anaemia : Assessment, Prevention and Control : A Guide for Programme Managers*, World Health Organization, Geneva, Switzerland, 2001.

[18] E. Baysal, “Alpha-thalassemia syndromes in the United Arab Emirates,” *Hemoglobin*, vol. 35, pp. 574–580, 2011.

[19] J. Traeger-Synodinos, I. Papassotiriou, C. Vrettou, C. Skarmoutsou, A. Stamoulakatou, and E. Kanavakis, “Erythroid marrow activity and functional anemia in patients with the rare interaction of a single functional α⁺-globin and β-globin gene,” *Haematologica*, vol. 86, no. 4, pp. 363–367, 2001.

[20] J. M. Old, “Screening and genetic diagnosis of haemoglobinopathies,” *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 67, no. 1, pp. 71–86, 2007.

[21] I. Bianco, M. P. Cappabianca, E. Foglietta et al., “Silent thalassemias: genotypes and phenotypes,” *Haematologica*, vol. 82, no. 3, pp. 269–280, 1997.

[22] A. Mosca, R. Paleari, R. Galanello et al., “New analytical tools and epidemiological data for the identification of HbA₂ borderline subjects in the screening for beta-thalassemia,” *Bioelectrochemistry*, vol. 73, no. 2, pp. 137–140, 2008.

[23] A. Giambona, C. Passarello, M. Vinciguerra et al., “Significance of borderline hemoglobin A₂ values in an Italian population with a high prevalence of β-thalassemia,” *Haematologica*, vol. 93, no. 9, pp. 1380–1384, 2008.